New models and characterization data being added every month – CTIBiotech

From bench to the bedside: Inserm U1068 Research lab
22/03/2018
CTIBiotech advances cancer treatments with state-of-the-art 3D-Bioprinting
CTIBiotech advances cancer treatments with state-of-the-art 3D-Bioprinting
22/03/2018

New models and characterization data being added every month – CTIBiotech

20 in-vitro cell models are already available for various cancers studied in the IMODI consortium with new models and characterization data being added every month


The IMODI in-vitro cell models retain the properties of patient tumor and allow highly reproductible studies providing understanding in cell biology, drug sensitivity and insight into signaling pathways.
Do not hesitate to contact CTIBiotech for In-vitro Patient Derived Cancer Cell Models; a full list of the models will be available in the IMODI Web catalogue in the coming weeks.
Several Patient Derived Cell models are already being used in the 3D-OncoCHIP FUI Project lead by CTIBiotech aiming to develop 3D printing techniques to produce reproducible microtumors and their microenvironment.

Learn more about 3D printing of tumoral models and 3D-OncoCHIP





Get connected!

Follow us on: @IMODI_Cancer & www.linkedin.com/company/imodi-cancer


Share this